Pharmacists press state boards to act against unapproved retatrutide

A commentary published September 4, 2026, in the pharmacy trade publication Pharmacy Times calls on state boards of pharmacy to investigate and discipline the pharmacies and clinicians tied to illegal sales of retatrutide ^[1]. The author is John Hertig, PharmD, chair of the board of directors of the Collaborative for Evidence-Based Medicines ^[1].

Retatrutide, made by Eli Lilly and Company, is an investigational medicine that is still being studied in controlled clinical trials. It is not approved by the FDA and cannot lawfully be compounded or marketed for human use, according to the commentary ^[1]. The article says products claiming to contain retatrutide are being promoted by online sellers, compounding pharmacies, medical spas and other channels, sometimes labeled "compounded retatrutide" and sometimes labeled "research use only." Neither label makes the product legitimate, the author writes ^[1].

The commentary draws a line between two regulators. The FDA can pursue companies that illegally market unapproved drugs, while state boards of pharmacy oversee the pharmacies and pharmacists they license, including nonresident pharmacies that ship products across state lines ^[1]. Hertig writes that when illegal retatrutide moves through those licensed channels, boards should use all tools available under their state laws to investigate, trace how products reach patients, and act against licensees when warranted ^[1].

The article points to two states as examples. Ohio's board of pharmacy has warned licensees that compounding, selling, ordering, administering or otherwise facilitating distribution of retatrutide may lead to disciplinary action, including immediate license suspension; the state has collected more than $1 million in penalties from sellers of unapproved drugs, including retatrutide, according to the commentary ^[1]. In Indiana, a nonresident pharmacy license renewal was denied in a matter involving retatrutide ^[1]. The author writes that those efforts address only a small portion of the illegal retatrutide moving through regulated channels across states, though no estimate of the total market size appears in the article ^[1].

On the federal side, the FDA has documented at least one supplier distributing retatrutide to pharmacies that intended to use it in compounded drugs, the commentary says ^[1]. A separate FDA page on its concerns about unapproved GLP-1 drugs used for weight loss was updated September 1, 2026, and is cited in the article's reference list ^[1].

Hertig concludes: "State boards of pharmacy are at the center of this issue and must be positioned and resourced to protect patient safety first" ^[1].

Why it matters for patients

Retatrutide has no FDA approval, which means there is no agency-reviewed manufacturing standard, ingredient list or dosing information for products sold under that name outside of clinical trials ^[1]. The commentary describes the buyers of these products as patients exposed to serious risk, and says the products are not made legitimate by the involvement of a pharmacy or clinic ^[1].

State boards license the pharmacies and pharmacists that patients encounter, and they can issue public warnings and suspend licenses ^[1]. That makes them the regulators closest to the distribution channels described in the article. The commentary also notes that a pharmacy may hold licenses in many states and ship nationwide, so action by one board, such as Ohio's or Indiana's, does not automatically stop distribution elsewhere ^[1].

Anyone taking or considering a product labeled as retatrutide is outside the oversight the FDA applies to approved drugs, according to the risks described in the article ^[1]. The piece does not describe specific symptoms, case counts or patient harms tied to retatrutide products.

What happens next

No new enforcement actions, timelines or rule changes are announced in the commentary. It urges state boards to issue public warnings, review advertising, complaints, inspection findings, sourcing records and other states' disciplinary actions, and work with boards of medicine and nursing, state attorneys general, law enforcement, the FDA and the National Association of Boards of Pharmacy ^[1]. Whether any additional boards adopt the Ohio or Indiana approach has not been reported.